Search results
Results From The WOW.Com Content Network
Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. [5] It is generally recommended for use with other antiretroviral medications. [5] It may be used to prevent mother to child spread during birth but is not recommended following other exposures. [5] It is ...
Nevirapine: HIV non-nucleoside reverse transcriptase inhibitor: Nitazoxanide: Broad-spectrum antiviral: thiazolide Norvir: HIV Oseltamivir (Tamiflu) [13] Influenza neuraminidase inhibitor: Peramivir (Rapivab) [14] Influenza Penciclovir: Herpes: Pleconaril: Picornavirus: Schering-Plough: Podophyllotoxin: Genital wart: Raltegravir: HIV Integrase ...
Three NNRTI compounds of the first generation have been approved by the FDA for treating HIV-1 infection. Nevirapine was approved in 1996, delavirdine in 1997 and efavirenz in 1998 (table 1). Two of these drugs, nevirapine and efavirenz, are cornerstones of first line HAART while delavirdine is hardly used nowadays.
Nevirapine has the trade name Viramune. Delavirdine, currently rarely used, has the trade name Rescriptor. Etravirine has the trade name Intelence, and was approved by the FDA in 2008. Rilpivirine has the trade name Edurant, and was approved by the FDA in May 2011. Doravirine has the trade name Pifeltro, is developed by Merck & Co.
An HIV virion binds to a CD4+ human cell. The two bottom pictures depict two proposed models of HIV fusion with the cell. They are used in combination therapy for the treatment of HIV infection. This class of drugs interferes with the binding, fusion and entry of an HIV virion to a human cell.
The AOL.com video experience serves up the best video content from AOL and around the web, ... US records its 1st human bird flu death in Louisiana. Celebrity Buzz. See All.
Nelfinavir is an orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (K i = 2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection. [2] It was patented in 1992 and approved for medical use in 1997. [3]
Raltegravir (Isentress), developed by Merck & Co., was the first INSTI approved by the FDA in October 2007.; Elvitegravir (Vitekta), licensed by Gilead Sciences from Japan Tobacco, was approved by the U.S. Food and Drug Administration in August 2012, for use in adults starting HIV treatment for the first time as part of the fixed dose combination with emtricitabine and tenofovir disoproxil ...